Active cytomegalovirus retinitis after the start of antiretroviral therapy

Active cytomegalovirus retinitis after the start of antiretroviral therapy

Patients with AIDS-related cytomegalovirus (CMV) retinitis receiving combined antiretroviral therapy (cART), but not specific anti-CMV therapy, consistently showed active retinitis for several months. Delayed diagnosis and treatment of CMV retinitis may have severe consequences. Patients first enter...

Full description

Bibliographic Details
Main Authors:	Heiden, D, Tun, N, Smithuis, F, Keenan, J, Oldenburg, C, Holland, G, Drew, W
Format:	Journal article
Published:	BMJ Publishing Group 2018

Similar Items

When to start antiretroviral therapy in HIV-associated tuberculosis.
by: Török, M, et al.
Published: (2011)

Causes and timing of mortality and morbidity among late presenters starting antiretroviral therapy in the REALITY trial
by: Post, F, et al.
Published: (2018)

Pharmacoeconomic analysis of 3 treatment strategies for cytomegalovirus retinitis in patients with AIDS.
by: Griffiths, R, et al.
Published: (1998)

Monocyte dysfunction, activation, and inflammation after long-term antiretroviral therapy in an African cohort
by: Nabatanzi, R, et al.
Published: (2019)

How soon after HIV seroconversion is antiretroviral therapy initiated?
by: Babiker, A, et al.
Published: (1999)

Interleukin-10 responses to therapeutic vaccination during highly active antiretroviral therapy and after analytical therapy interruption.
by: Yang, H, et al.
Published: (2009)

Visual acuity after retinal gene therapy for Choroideremia
by: Edwards, T, et al.
Published: (2016)

Reappearance of HIV antibody in an infected, seronegative individual after treatment with highly active antiretroviral therapy.
by: Rice, P, et al.
Published: (1999)

Acute retinal necrosis by cytomegalovirus in an immunocompetent adult: case report and review of the literature.
by: Tajunisah, I., et al.
Published: (2009)

CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
by: Wolbers, M, et al.
Published: (2007)

Monitoring of highly active antiretroviral therapy in HIV infection.
by: Walker, A, et al.
Published: (2011)

Virological remission after antiretroviral therapy interruption in female African HIV seroconverters
by: Gossez, M, et al.
Published: (2018)

AIDS-defining illnesses: a comparison between before and after commencement of highly active antiretroviral therapy (HAART)
by: Lian, Y.L.A., et al.
Published: (2007)

Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences.
by: Touloumi, G, et al.
Published: (2006)

Response to combination antiretroviral therapy: variation by age.
by: Sabin, C, et al.
Published: (2008)

Ganciclovir therapy for severe cytomegalovirus infection in immunocompetent patients - Reply
by: Eddleston, M, et al.
Published: (1997)

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.
by: Walker, A, et al.
Published: (2010)

[Gene therapy for retinal dystrophies].
by: Charbel Issa, P, et al.
Published: (2012)

Gene therapy for retinal dystrophies
by: Issa, P, et al.
Published: (2012)

Gene therapy for retinal disease.
by: McClements, M, et al.
Published: (2013)

Hypophosphataemia with non-tenofovir-containing antiretroviral therapy.
by: Wainwright, E, et al.
Published: (2013)

Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy.
by: Buclin, T, et al.
Published: (2011)

Clinical differences between younger and older adults with HIV/AIDS starting antiretroviral therapy in Uganda and Zimbabwe: a secondary analysis of the DART trial
by: Parikh, S, et al.
Published: (2013)

Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption
by: Gondim, MVP, et al.
Published: (2021)

Determinants of survival without antiretroviral therapy after infancy in HIV-1-infected Zambian children in the CHAP Trial.
by: Walker, A, et al.
Published: (2006)

Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy.
by: Ogg, G, et al.
Published: (1999)

Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children.
by: Spiegel, H, et al.
Published: (1999)

HIV infection significantly reduces lipoprotein lipase which remains low after 6 months of antiretroviral therapy
by: Boothby, M, et al.
Published: (2008)

Short-course antiretroviral therapy in primary HIV infection.
by: Fidler, S, et al.
Published: (2013)

Management of antiretroviral therapy for HIV infection : analyzing when to change therapy
Published: (2003)

Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome.
by: Aboulker, J, et al.
Published: (2004)

Predicting the need for third-line antiretroviral therapy by identifying patients at high risk for failing second-line antiretroviral therapy in South Africa
by: Onoya, D, et al.
Published: (2017)

Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults.
by: International Collaboration on HIV and Cancer
Published: (2000)

Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy.
by: Frater, A, et al.
Published: (2002)

Immunological responses to retinal gene therapy
by: Chandler, L
Published: (2021)

Clinical applications of retinal gene therapy.
by: Lipinski, D, et al.
Published: (2013)

Neuroprotection gene therapy in retinal degeneration
by: Shan, H
Published: (2013)

The moral and fiscal implications of antiretroviral therapies for HIV in Africa
by: Collier, P, et al.
Published: (2018)

Antiretroviral therapy in Malaysia: identifying barriers to universal access
by: Kamarulzaman, A.
Published: (2009)

Determinants of antiretroviral therapy coverage in Sub-Saharan Africa
by: Furuoka, Fumitaka, et al.
Published: (2015)